Tuesday, 18 April 2017

Anaphylaxis Treatment Becomes Easy With Prefilled Syringes

Syringes are needed by doctors to successfully administer various medications to patients. The limited production of conventional syringes and their reuse by healthcare practitioners leading to cross-infections gave birth to prefilled syringes. Conventional syringes are even used by drug addicts to inject themselves intravenously. 

Prefilled syringes come in predetermined doses or quantities. Some of these devices have an added self-locking mechanism that kicks in after one use, which prevents their reuse and protects others from possible infections. These syringes are currently in high demand due to the high incidence of diabetes and Rheumatoid Arthritis (RA). Silicone oil is used as a lubricant in the syringes to enhance their shelf life.

Novel Developments

Scandinavian Health Limited (SHL) Group, a Swedish manufacturer of autoinjectors and prefilled syringes, launched two major products targeting RA patients: “Amber Auto Injector”—a device with customized shapes for gripping the injector—which would aid RA patients with severe dexterity issues and “Emerade Auto Injector”—a two-step disposable syringe—which can administer doses in three strength levels– 150, 300, and 500 micrograms (mcg). It can be used to administer adrenaline in case of anaphylaxis or emergency. It has reportedly the longest needle in the market.

The company has also released an autoinjector (“Molly C”) with an inbuilt data recording system dubbed “Recording Unit.” This system allows the device to save patient-related data successfully from their smartphone. It allows users to post their query on Alubena—a common platform to solve drug-delivery issues related to the product.

Market Overview

The worldwide prefilled syringes market size is expected at USD 22.5 billion by 2025. It is driven by the increasing global use of prefilled syringes and technological breakthroughs in autoinjectors.

Glass prefilled syringes dominated the global market in 2015, but plastic syringes segment is anticipated to reign from 2016 to 2025 (forecast period). Diabetes is predicted to be the largest market application throughout the forecast period. Owing to technological advancements, North America is expected to exhibit high growth over the forecast period. Some key industry players are Scandinavian Health Limited (SHL Group), Schott AG, and Unilife Corporation.

No comments:

Post a Comment